Quest Diagnosticsvs.Natera
DGX vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 1.7× larger than Quest Diagnostics by market cap.
Side by side
| DGX | NTRA | |
|---|---|---|
| Market cap | $23.1B | $38.8B |
| Price | $207.44 | $269.95 |
| Today | −0.3% | −4.2% |
| Return YTD | +19.5% | +17.8% |
| Return 1Y | +21.0% | +65.2% |
| P/E | 22.6 | — |
| P/S | 2.1 | 15.5 |
| P/B | 3.1 | 21.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Quest DiagnosticsDGX
Nationwide clinical laboratory network for routine and advanced diagnostics.
Full DGX profile →NateraNTRA
Molecular and genetic diagnostics across prenatal screening, oncology and transplantation.
Full NTRA profile →More comparisons in Diagnostics
See where DGX and NTRA sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →